Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

NCT02642458 · clinicaltrials.gov ↗
UNKNOWN
Status
300
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

University Hospital Tuebingen